Galectin‐3 regulates inflammasome activation in cholestatic liver injury
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Macrophage activation is an important feature of primary biliary cholangitis (PBC) pathogenesis and other cholestatic liver diseases. Galectin‐3 (Gal3), a pleiotropic lectin, is produced by monocytic cells and macrophages. However, its role in PBC has not been addressed. We hypothesized that Gal3 is a key to induce NOD‐like receptor family, pyrin domain containing 3 (NLRP3) inflammasome in macrophages and in turn to propagate proinflammatory IL‐17 signaling. In liver tissues from patients with PBC and dnTGF‐βRII mice, a model of autoimmune cholangitis, the expression of Gal3, NLRP3, and the adaptor protein adaptor apoptosis‐associated speck like protein was induced, with the downs tream activation of caspase‐1 and IL‐1β. Inwild‐typehepaticmacrophages, deoxycholic acid induced the association of Gal3 and NLRP3with direct activation of the inflammasome, resulting in an increase in IL‐1β. Downstreamretinoid‐related orphan receptor CmRNA, IL‐17A, and IL‐17Fwere induced. In Gal3 ‐/‐ macrophages, no inflammasome activation was detected. To confirm the key role of Gal3 in the pathogenesis of cholestatic liver injury, we generated dnTGF‐βRII/galectin‐3 ‐/ (dn/Gal3 ‐/ ) mice, which showed impaired inflammasome activation alongwith significantly improved inflammation and fibrosis. Taken together, our data point to a novel role of Gal3 as an initiator of inflammatory signaling in autoimmune cholangitis, mediating the activation of NLRP3 inflammasome and inducing IL‐17 proinflammatory cascades. These studies provide a rationale to target Gal3 in autoimmune cholangitis and potentially other cholestatic diseases.—Tian, J., Yang, G., Chen, H.‐Y., Hsu, D. K., Tomilov, A., Olson, K.A., Dehnad, A., Fish, S. R., Cortopassi, G.,Zhao, B., Liu, F.‐T., Gershwin, M.E., Török, N. J., Jiang, J. X. Galectin‐3 regulates inflammasome activation in cholestatic liver injury. FASEB J. 30, 4202–4213 (2016). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A., & Sallusto, F. (2007) · Nature Immunology · doi:10.1038/ni1496 · Cited by 1,857
The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
Davis, B. K., Wen, H., & Ting, J. P.-Y. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101405 · Cited by 1,618
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Hepatology · doi:10.1002/hep.26592 · Cited by 945
Meng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711 · cited 2×
“IL-17 is considered a proinflammatory and profibrogenic cytokine (20).”
BackgroundNLRP3 inflammasome activation is required for fibrosis development in NAFLD
Wree, A., McGeough, M. D., Peña, C. A., Schlattjan, M., Li, H., Inzaugarat, M. E., Messer, K., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1170-1 · Cited by 486 · cited 2×
“Transgenic mice expressing constitutively active NLRP3 showed severe hepatocyte pyroptosis, inflammation, and fibrosis (6), and NLRP3 depletion was protective (7, 9).”
BackgroundCritical role of galectin-3 in phagocytosis by macrophages
Sano, H., Hsu, D. K., Apgar, J. R., Yu, L., Sharma, B. B., Kuwabara, I., Izui, S., & Liu, F.-T. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317592 · Cited by 429
Yang, C.-Y., Ma, X., Tsuneyama, K., Huang, S., Takahashi, T., Chalasani, N. P., Bowlus, C. L., Yang, G.-X., Leung, P. S. C., Ansari, A. A., et al. (2014) · Hepatology · doi:10.1002/hep.26979 · Cited by 213 · cited 1×
“Indeed, a recent study showed increased hepatic Th17 in patientswith advanced PBC (49), and the induction of Th17 in PBCwas preferential to the liver (48).”
BackgroundSelf-citationAltered Monocyte Responses to Defined TLR Ligands in Patients With Primary Biliary Cirrhosis *
Mao, T. K., Lian, Z.-X., Selmi, C., Ichiki, Y., Ashwood, P., Ansari, A. A., Coppel, R. L., Shimoda, S., Ishibashi, H., & Gershwin, E. M. (2005) · Hepatology · doi:10.1002/hep.20859 · Cited by 185 · cited 2×
“Thekey role ofmacrophages inPBChasbeennoted (42, 43).”
BackgroundEvidence for anti‐inflammatory effects of C5a on the innate IL‐17A/IL‐23 axis
Bosmann, M., Sarma, J. V., Atefi, G., Zetoune, F. S., & Ward, P. A. (2012) · The FASEB Journal · doi:10.1096/fj.11-199216 · Cited by 67
Cited by
Wen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695
Banales, J. M., Huebert, R. C., Karlsen, T., Strazzabosco, M., LaRusso, N. F., & Gores, G. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0125-y · Cited by 517
The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review
Ma, W.-T., Gao, F., Gu, K., & Chen, D.-K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01140 · Cited by 361
The role of galectins in immunity and infection
Liu, F.-T., & Stowell, S. R. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00829-7 · Cited by 313
Self-citationMechanisms of bile acid mediated inflammation in the liver
Li, M., Cai, S.-Y., & Boyer, J. L. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.06.001 · Cited by 271
Aragno, M., & Mastrocola, R. (2017) · Nutrients · doi:10.3390/nu9040385 · Cited by 239
“Among these receptors, a role for two AGEs receptors, namely RAGE and Galectin-3, in inflammasomes activation has been proposed [72-75].”
BackgroundThe therapeutic potential of galectin-3 inhibition in fibrotic disease
Slack, R. J., Mills, R., & Mackinnon, A. C. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105881 · Cited by 136
Metaflammation: Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome
Mastrocola, R., Aragno, M., Alloatti, G., Collino, M., Penna, C., & Pagliaro, P. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170407123522 · Cited by 76
“knocked out in the autoimmune cholangitis model [86].”
BackgroundNLRP3 inflammasome activation mechanism and its role in autoimmune liver disease
Guan, Y., Gu, Y., Li, H., Liang, B., Han, C., Zhang, Y., Liu, Q., Wei, W., & Ma, Y. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022137 · Cited by 48
Uchino, Y., Woodward, A. M., Mauris, J., Peterson, K., Verma, P., Nilsson, U. J., Rajaiya, J., & Argüeso, P. (2018) · Immunology · doi:10.1111/imm.12899 · Cited by 31
Beyond M1/M2: The role of reactive oxygen species in liver fibrosis and immune modulation
Lu, H., Huang, J., Wang, Y.-C., Casals, E., Casals, G., & Zeng, M. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103933 · Cited by 19
“However, some M2 subsets, for example, promote fibrosis through galectin-3-mediated HSC activation [80], and others, like TREM2 + LAMs, exhibit hybrid pro-fibrotic and pro-resolving properties [81].”
Metadata
- Authors
- Tian, J., Yang, G., Chen, H., Hsu, D. K., Tomilov, A., Olson, K. K. A., Dehnad, A., Fish, S. R., Cortopassi, G., Zhao, K. B., Liu, F., Gershwin, M. E., Török, N. J., & Jiang, J. X.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2016-09-14
- Volume
- 30
- Issue
- 12
- Pages
- 4202-4213
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2520071434
- Cited by
- 83
- References
- 9
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.